Published in Hepatitis Weekly, February 7th, 2000
Intravenous glycyrrhizin has been used in Japan for the treatment of chronic hepatitis for more than 20 years, although only a few reports of its pharmacokinetic profile after multiple intravenous doses in small numbers of Japanese patients have been published.
In this study, researcher T. G. van Rossum and colleagues from The Netherlands' University Hospital Rotterdam compared these Japanese data against the pharmacokinetic characteristics of glycyrrhizin after single and multiple intravenous doses in 35 European patients with chronic hepatitis C infection...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly